TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12975635

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) consumption
Number of subjects: 19

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) consumption
Number of subjects: 19
Study: 10935781

Group type: EXPERIMENTAL
Intervention: Insulin(GIK)
Number of subjects: 28

Group type: COMPARATOR
Intervention: alpha-ketoglutarate enrichment of blood cardioplegia
Number of subjects: 28
Study: 8967706

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1000 mg/d) and vitamin D3 (500 IU/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3
Number of subjects: 96
Study: 1390144

Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg b.i.d. orally)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Penicillin (2.5 MU x 8 daily intravenously, then 6 MU daily orally)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Penicillin (control group)
Number of subjects: 72
Study: 2983909

Group type: EXPERIMENTAL
Intervention: High-dose naloxone (5.4 mg/h)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low-dose naloxone (0.8 mg/h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31843269

Group type: EXPERIMENTAL
Intervention: HD-TDV
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: TDV
Number of subjects: 351
Study: 29741749

Group type: EXPERIMENTAL
Intervention: Scenario, simulation, and debriefing
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scenario and simulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scenario
Number of subjects: 60
Study: 28060463

Group type: EXPERIMENTAL
Intervention: Positive Activity Intervention (PAI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 29
Study: 26673919

Group type: EXPERIMENTAL
Intervention: Interactive cognitive‐motor training (ICMT) - four stepping games, three 20-minute sessions per week for 16 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (CG) - received an evidence‐based brochure on fall prevention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low adherers to ICMT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High adherers to ICMT
Number of subjects: 90
Study: 23302973

Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept 50 mg administered 90 minutes before surgery
Number of subjects: 77

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Presence of pain at 1 month
Number of subjects: 77
Study: 21679463

Group type: EXPERIMENTAL
Intervention: TAU plus the REACT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study: 18164672

Group type: EXPERIMENTAL
Intervention: rhGH treatment (4.5 IU intramuscularly daily for 4 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 114
Study: 16505196

Group type: EXPERIMENTAL
Intervention: Brachial blood pressure measurement
Number of subjects: 484

Group type: COMPARATOR
Intervention: Carotid augmentation index
Number of subjects: 484

Group type: COMPARATOR
Intervention: Systemic arterial compliance
Number of subjects: 484
Study: 15243933

Group type: EXPERIMENTAL
Intervention: CVD 909 (oral attenuated typhoid vaccine) at doses of 10(6-9) cfu
Number of subjects: 32
Study: 11377309

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 10211027

Group type: EXPERIMENTAL
Intervention: Nafamostat 0.02 mg kg‐1
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (5% glucose 0.02 ml kg‐1)
Number of subjects: 213
Study: 7943305

Group type: EXPERIMENTAL
Intervention: Daily rhGH (0.15 mg somatotropin · kg‐1 · day‐1) intramuscular injections
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with daily rhGH
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 20
Study: 3058105

Group type: COMPARATOR
Intervention: Cyclosporin (CSP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study: 31419155

Group type: EXPERIMENTAL
Intervention: Verb Network Strengthening Treatment (VNeST), 15 hours of therapy delivered by experienced speech-language pathologists.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intensive therapy (as part of the study condition).
Number of subjects: 56

Group type: COMPARATOR
Intervention: Distributed therapy (as part of the study condition).
Number of subjects: 56
Study: 29947051

Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional clinical trials
Number of subjects: 0
Study: 25905441

Group type: EXPERIMENTAL
Intervention: Rapid genetic counseling and testing (RGCT)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 265
Study: 24595305

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) during energy deficit
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ingestion of 15 g of whey protein after REX in ED
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ingestion of 30 g of whey protein after REX in ED
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined exercise and protein intake
Number of subjects: 15

Group type: COMPARATOR
Intervention: Energy deficit (ED)
Number of subjects: 15
Study: 22434459

Group type: EXPERIMENTAL
Intervention: Cobalt-chrome on ultra-high-molecular-weight polyethylene
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Cobalt-chrome on highly cross-linked polyethylene
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard polyethylene (control)
Number of subjects: 91
Study: 20146794

Group type: EXPERIMENTAL
Intervention: Transmural nutritional support (energy and protein enriched diet, two additional servings of an oral nutritional supplement, vitamin D and calcium supplementation, consultations by a dietitian)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual nutritional care
Number of subjects: 200
Study: 18045724

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 0
Study: 16670110

Group type: EXPERIMENTAL
Intervention: N(2)O with oxygen
Number of subjects: 228

Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 228
Study: 12788879

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.4 pmol/kg x min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 0.8 pmol/kg x min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at 1.2 pmol/kg x min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (all doses)
Number of subjects: 12
Study: 10976083

Group type: EXPERIMENTAL
Intervention: exercise, taping, and education
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: exercise and education
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: taping and education
Number of subjects: 81

Group type: COMPARATOR
Intervention: education alone
Number of subjects: 81
Study: 8972417

Group type: EXPERIMENTAL
Intervention: Standard cesarean section with continuous double layer closure of uterine incision and closure of visceral and parietal peritoneum
Number of subjects: 200

Group type: COMPARATOR
Intervention: Modified technique with one layer closure of uterine incision and open visceral and parietal peritoneum
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Standard cesarean section
Number of subjects: 200

Group type: COMPARATOR
Intervention: Modified technique
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 200
Study: 1351796

Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 6083688

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine + Dextran 70
Number of subjects: 107

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine + Dextran 70 (hip replacement)
Number of subjects: 107

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 107

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 107
Study: 29179562

Group type: EXPERIMENTAL
Intervention: Interventional support during hospitalization
Number of subjects: 243

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 243
Study: 30541098

Group type: EXPERIMENTAL
Intervention: HC/HF diet (carbohydrate-rich meals until 1330 and fat-rich meals between 1630 and 2200)
Number of subjects: 29

Group type: COMPARATOR
Intervention: HF/HC diet (inverse sequence of meals)
Number of subjects: 29
Study: 26804606

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program administered by volunteers for eight weeks, three times each week
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG) with standard 'friendly visits'
Number of subjects: 36
Study: 24890747

Group type: EXPERIMENTAL
Intervention: 12-hour magnesium sulfate therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: 24-hour magnesium sulfate therapy
Number of subjects: 120
Study: 22803759

Group type: EXPERIMENTAL
Intervention: Schema-based instruction
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 53
Study: 20823169

Group type: EXPERIMENTAL
Intervention: Prefabricated wrist splint
Number of subjects: 96

Group type: COMPARATOR
Intervention: Short arm cast
Number of subjects: 96
Study: 18294504

Group type: EXPERIMENTAL
Intervention: Enhanced-magnification endoscopy (EME)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Conventional magnification endoscopy (CME) / magnification chromoendoscopy (MCE)
Number of subjects: 380
Study: 15919798

Group type: EXPERIMENTAL
Intervention: hOKT3gamma1(Ala-Ala) monoclonal antibody
Number of subjects: 0
Study: 12843392

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-methyl-D-aspartate-receptor blocker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Left index finger (no drug)
Number of subjects: 0
Study: 10655977

Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 mg Cu-glycine chelate (CuGC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 6 mg Cu-glycine chelate (CuGC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8666715

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 2065695

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3884577

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31443886

Group type: EXPERIMENTAL
Intervention: Baltimore City Drug Treatment Court (BCDTC)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Traditional adjudication
Number of subjects: 235
Study: 30153453

Group type: EXPERIMENTAL
Intervention: Increasing-distance interval training (100–200–300–400–500 m), twice a week for six weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Decreasing-distance interval training (500–400–300–200–100 m), twice a week for six weeks
Number of subjects: 40
Study: 28229646

Group type: COMPARATOR
Intervention: PT (Physical Training)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PT + NT (Physical Training + Nutritional Therapy)
Number of subjects: 34
Study: 24680961

Group type: EXPERIMENTAL
Intervention: Chitosan lactate wafer containing tizanidine HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate release tablet Sirdalud(®)
Number of subjects: 0
Study: 22985205

Group type: COMPARATOR
Intervention: Fluoxetine-only
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CBT + fluoxetine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CBT + placebo
Number of subjects: 81
Study: 20030470

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg with tapentadol IR 80 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg with tapentadol IR 80 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 325 mg with tapentadol IR 80 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tapentadol IR 80 mg alone
Number of subjects: 62
Study: 21978966

Group type: EXPERIMENTAL
Intervention: Guidant VITALITY 2 with Rhythm ID
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Medtronic pulse generators using Enhanced PR Logic or Wavelet discrimination algorithms
Number of subjects: 1962
Study: 15949725

Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BQ-123 (50 nmol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BQ-123 (10 nmol/min) + L-NMMA (2 micromol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BQ-123 (50 nmol/min) + L-NMMA (4 micromol/min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: BQ-123
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline ET-1 levels
Number of subjects: 18
Study: 14612933

Group type: EXPERIMENTAL
Intervention: Retinol (50,000 IU per day) for six months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Retinol
Number of subjects: 81
Study: 9728850

Group type: EXPERIMENTAL
Intervention: Desflurane at 1 L/min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane at 1 L/min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Esmolol infusion with desflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Esmolol infusion with isoflurane
Number of subjects: 90
Study: 7662503

Group type: EXPERIMENTAL
Intervention: HK subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HK + FSS subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study: 2914739

Group type: EXPERIMENTAL
Intervention: Preventive antiarrhythmic treatment
Number of subjects: 0
Study: 1112170

Group type: EXPERIMENTAL
Intervention: Thiordazine (THI) at single daily doses not exceeding 375 mg/day for 6 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pimozide (PIM) at single oral doses not exceeding 16 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both drug groups (THI and PIM)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BPRS scale
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Social adjustment ratings
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Side effects with THI
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Side effects with PIM
Number of subjects: 35
Study: 31492912

Group type: EXPERIMENTAL
Intervention: PCA (proton pump inhibitors, clarithromycin, and amoxicillin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCA plus BSEF (Bacillus subtilis and Enterococcus faecium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCA (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCA plus BSEF (TP group)
Number of subjects: 0
Study: 28292885

Group type: EXPERIMENTAL
Intervention: Normal endurance training combined with strength training (E+S)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal endurance training (E)
Number of subjects: 19
Study: 26133726

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at SP 6, SP 9, GB 39, and ST 36 for 30 minutes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA) at SP 6, SP 9, GB 39, and ST 36 for 30 minutes
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CG) relaxed for 30 minutes
Number of subjects: 72
Study: 22890616

Group type: EXPERIMENTAL
Intervention: Self-management intervention for weight control
Number of subjects: 167
Study: 20965780

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg once daily)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 18705691

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 224
Study: 16804427

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV; FluMist)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 12709753

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Midazolam and Placebo
Number of subjects: 95
Study: 11101476

Group type: EXPERIMENTAL
Intervention: High-meat diet (600 g/d)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vegetarian diet (0 g/d)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bovine serum albumin or casein added to fecal batch cultures
Number of subjects: 5
Study: 8833212

Group type: EXPERIMENTAL
Intervention: Cyclical clodronate therapy (200 mg IV infusion every 3 weeks)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (183 postmenopausal osteoporotic patients)
Number of subjects: 235
Study: 1317089

Group type: EXPERIMENTAL
Intervention: Modified soft jelly capsule containing nonoxynol-9 (DF-486)
Number of subjects: 40
Study: 2859931

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg qid (mean dose 340 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30442986

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted bitterness of caffeine
Number of subjects: 438870

Group type: EXPERIMENTAL
Intervention: Higher PROP perception
Number of subjects: 438870

Group type: EXPERIMENTAL
Intervention: Higher quinine perception
Number of subjects: 438870

Group type: EXPERIMENTAL
Intervention: Higher caffeine perception
Number of subjects: 438870

Group type: EXPERIMENTAL
Intervention: Higher bitterness perception of tea
Number of subjects: 438870
Study: 27340881

Group type: EXPERIMENTAL
Intervention: HRT (Nuvelle)
Number of subjects: 59

Group type: COMPARATOR
Intervention: COCP (Microgynon 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 59
Study: 24825416

Group type: EXPERIMENTAL
Intervention: LY1 dosing algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY2 dosing algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine (GL) dosing algorithm
Number of subjects: 0
Study: 22301439

Group type: EXPERIMENTAL
Intervention: CD4(+) T-cell-guided therapy interruption (TI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: therapy continuation
Number of subjects: 106
Study: 21301680

Group type: EXPERIMENTAL
Intervention: GP reply letter sent from a community mental health service
Number of subjects: 39

Group type: COMPARATOR
Intervention: No GP reply letter
Number of subjects: 39
Study: 17651961

Group type: EXPERIMENTAL
Intervention: Refined olive oil (ROO) meal
Number of subjects: 28

Group type: COMPARATOR
Intervention: High‐palmitic sunflower oil (HPSO) meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Postprandial response
Number of subjects: 28
Study: 15653962

Group type: EXPERIMENTAL
Intervention: INR 3.0 to 4.5
Number of subjects: 2735

Group type: EXPERIMENTAL
Intervention: INR 2.5 to 4.0
Number of subjects: 2735

Group type: EXPERIMENTAL
Intervention: INR 2.0 to 3.5
Number of subjects: 2735

Group type: EXPERIMENTAL
Intervention: All INR strata
Number of subjects: 2735
Study: 11994612

Group type: EXPERIMENTAL
Intervention: Telephone interviews with health care providers regarding breast implant concerns
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Desire for information
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Feelings expressed by women
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Need for accurate information from health care professionals
Number of subjects: 820
Study: 10201101

Group type: EXPERIMENTAL
Intervention: Differential observing response procedure; no specific dosage or duration mentioned.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Baseline condition; no specific dosage or duration mentioned.
Number of subjects: 3
Study: 7768234

Group type: EXPERIMENTAL
Intervention: Long-term low intensity aerobic training (treadmill, 30 min, 3-6 times a week for 9 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Detraining (after 1 month in 5 patients)
Number of subjects: 30
Study: 2324998

Group type: EXPERIMENTAL
Intervention: Minimal public self disclosure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arithmetic task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self disclosure task with low perceived social approval
Number of subjects: 0
Study: 218717

Group type: EXPERIMENTAL
Intervention: Thymosin 60 mg/m2 (T60)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Thymosin 20 mg/m2 (T20)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No thymosin (P)
Number of subjects: 55
Study: 31468177

Group type: EXPERIMENTAL
Intervention: Curved needle
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-curved needle
Number of subjects: 69
Study: 27650432

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) including psychoeducation, breathing training, and cognitive restructuring over a 6-month period
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine clinical services (Control)
Number of subjects: 61
Study: 27294597

Group type: EXPERIMENTAL
Intervention: Dietary counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (low risk for OSA)
Number of subjects: 0
Study: 24415784

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily for 24 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 147
Study: 23094055

Group type: EXPERIMENTAL
Intervention: VS411 (didanosine 200 mg/HC 900 mg once-daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 58